Novo Nordisk A/S (NVO) — closed signal from July 6, 2025
Partial Published before the outcome was known, scored automatically when the window closed on October 4, 2025.
Predicted vs. what happened
What happened
Reached 24% of the predicted growth at its peak, without hitting the target.
The thesis — published July 6, 2025
The share price has slipped to around 68-70 dollars, a range that past patterns show is often a bargain. Demand for the weight loss drug Wegovy is so strong the firm cannot make enough, and this one medicine now supplies nearly half of profits. New studies for Alzheimer’s and Parkinson’s add future promise, and many investors see the stock as a safe grower. Similar dips have rebounded about 12%, so we expect 80-82 by September.
Primary drivers
- Stock looks cheap after a sharp slide, and similar drops have bounced about 12%.
- Wegovy weight loss drug supplies 44% of profits and demand is higher than supply.
- Expanding into Alzheimer’s and Parkinson’s could open new sources of long-term sales.
- Investors looking for steady growth give the stock high interest even in rough markets.
How it played out
NVO: target was not reached
Lyra published NVO at $68.4 on 2025-07-06 with a short-term thesis for 16% growth and a target of $78.46. The thesis pointed to a cheap-looking pullback after a sharp slide, Wegovy demand above supply, Wegovy supplying 44% of profits, possible longer-term work in Alzheimer's and Parkinson's, and investor interest in steady growth.
Inside the window from 2025-07-06 to 2025-10-04, NVO peaked at $71 on 2025-07-25, a 3.8% gain. It stayed below the target. The signal ended at $59.63. The thesis only partially played out at the early peak, then missed by the close.
What happened during the window
On 2025-07-29, Novo Nordisk lowered its 2025 sales and operating profit outlook and named Maziar Mike Doustdar as its next chief executive. On 2025-09-10, the company announced a restructuring with 9,000 job cuts and a lower 2025 operating profit growth forecast.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.